Trial Profile
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Effector Therapeutics
- 27 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2020.
- 16 Jul 2019 Planned End Date changed from 1 Apr 2022 to 1 Apr 2020.